Breast Cancer

Positive Abraxane data, nab technology presented

Published in Cancer Weekly, December 16th, 2003

American BioScience, Inc., presented data at the joint American Association of Cancer Research/National Cancer Institute and EORTC (European Organisation for Research and Treatment of Cancer) Symposium in Boston highlighting research on the delivery of active pharmaceutical compounds via a novel, nanoparticle protein-engineered technology platform.

Nanoparticle albumin-bound (nab) technology, for the first time, combines a physiologically interactive human protein, albumin, with an active pharmaceutical agent, resulting in compounds which are free of toxicities associated with the use of solvent-based formulations. The compound closest to commercialization is nab...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry